ChroMedX Welcomes Dr. Nick Smit to Biosensor Development Team

Toronto, Ontario
March 25, 2015

ChroMedX Corp. (the “Company”) (CSE: CHX, OTC: MNLIF, Frankfurt: EIY2), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the engagement of Dr. Nick Smit as part of the HemoPalm biosensor development team.

Dr. Nick Smit received his Ph.D. in Analytical Chemistry from the University of Delaware and began his career at i-Stat in Princeton, New Jersey and later Ottawa, Ontario where he rose to the position of Senior Scientist.

During his time at i-Stat Nick was co-inventor of numerous patents with Steve Cozzette who leads the ChroMedX biosensor development project.

 “We are very pleased to have Dr. Smit join the team.  Nick brings a wealth of expertise to our company and adds to the impressive group of leading experts we have contributing to the commercialization of the HemoPalm technology” said Dr. Wayne Maddever, ChroMedX Corp., President & CEO

After leaving i-Stat, Dr. Smit has held senior executive roles at several life sciences companies.  Dr. Smit’s expertise includes microsensor design and manufacturing, process validation and FDA 510(k) approvals.

About ChroMedX Corp.

ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing.  The devices are protected by the Company’s issued US and pending international patents, dealing with blood collection, analysis and plasma/serum processing.

Follow ChroMedX Corp.:


Investor Enquiries:

W. Clark Kent
Corporate Development